Bruker Daltonics Announces Launch of CBRN View Integration Software.

GOTHENBURG, Sweden -- At the 9th International CBW Protection Symposium, Bruker Daltonics today announces the launch of its unique CBRN View[TM] integration software for defense and homeland security forces. Bruker's CBRN View software is an advanced client application which receives and displays Chemical, Biological, Radiation and Nuclear (CRBN) detection results in real time on a graphical user interface. The CBRN View application shows the current detection status in many different views - ranging from visual alarm signals to a detection event list. The up-to-date status information of each detector is displayed in a separate view to allow the operator to customize the screen layout.

Dr. Joachim Stach, Sales & Marketing Director for CBRN Detection at Bruker Daltonics, commented: "Our new CBRN View software is the result of the lessons learned during the security operations at the 2006 Football (Soccer) World Cup, which showed that integrated multi-detector information management and visualisation are increasingly important in providing complete CBRN detection capabilities to event and homeland security forces."

Bruker Daltonics will exhibit at the 9th International Symposium on Protection against Chemical and Biological Warfare Agents in Gothenburg, Sweden, on May 22-25, 2007.

ABOUT BRUKER BIOSCIENCES (NASDAQ: BRKR)

Bruker BioSciences Corporation, headquartered in Billerica, Massachusetts, is the publicly traded parent company of Bruker Daltonics Inc., Bruker AXS Inc. and Bruker Optics Inc. For more information, please visit www.bruker-biosciences.com

CAUTIONARY STATEMENT

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to our reorganization strategies, risks related to the integration of businesses we have acquired or may acquire in the future, technological approaches, product development, market acceptance, cost and pricing of our products, changes in governmental regulations, capital spending and government funding policies, FDA and other regulatory approvals to the extent applicable, competition, the intellectual property of others, patent protection and litigation. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2006, our most recent quarterly reports on Form 10-Q and, our current reports on Form 8-K. We disclaim any intent or obligation to update these forward-looking statements.